Figure 4-14 Graph illustrates the mean change in visual acuity (number of letters read) from several phase 3 clinical trials. Comparison of data between different trials should be interpreted with caution; the potentially different study inclusion criteria and baseline characteristics of eyes for different studies may affect the stated visual acuity gains. ANCHOR = Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD; MARINA = Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD; PC = predominantly classic; PIER = Phase 3b, Multi-center, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization With or Without Classic Choroidal Neovascularization Secondary to AMD; TAP = Treatment of AMD with Photodynamic Therapy; VISION = VEGF Inhibition Study in Ocular Neovascularization.